- Imeik Technology’s net income for the fiscal year is 1.86 billion yuan, a significant increase from 1.26 billion yuan the previous year.
- This represents a year on year growth of 47% in net income.
- The company’s revenue also saw substantial growth, reaching 2.87 billion yuan, a 48% increase from the previous year.
- A final dividend per share of 2.323 yuan has been declared by the company.
- The company’s performance has been well received, with 35 buys, 1 hold, and 0 sells.
- All comparisons to past results are based on values reported by the company in their original disclosures.
A look at Imeik Technology Development C Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Imeik Technology Development Co.,Ltd, a company that specializes in manufacturing and distributing biomedical products, has received an overall positive outlook according to the Smartkarma Smart Scores. These scores, ranging from 1 to 5, indicate the company’s performance in various factors. Imeik Technology Development C has received a score of 2 for value, 3 for dividend, 5 for growth, 5 for resilience, and 3 for momentum.
The high scores of 5 in both growth and resilience suggest a promising long-term outlook for Imeik Technology Development C. This indicates that the company has a strong potential for growth and is well-equipped to withstand any potential challenges in the future. Additionally, the company’s score of 3 for dividend suggests that it also has the potential to provide steady returns to its investors. With its diverse range of products, including medical devices, Imeik Technology Development C is well-positioned to continue its success in the biomedical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
